Skip to main content
Clinical Trials/NCT03520088
NCT03520088
Unknown
Not Applicable

PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS

Corporacion Parc Tauli1 site in 1 country90 target enrollmentStarted: September 3, 2018Last updated:
ConditionsRectal Cancer

Overview

Phase
Not Applicable
Sponsor
Corporacion Parc Tauli
Enrollment
90
Locations
1
Primary Endpoint
Changes in sexual dysfunction pre- and post-Total Mesorectal Excision

Overview

Brief Summary

Purpose: The "Total Mesorectal Excision" (TME) is the standard surgical technique for the treatment of rectal cancer. Up to 50% of sexual dysfunction is described after TME and up to 30% of urinary dysfunction. The main objective of the study is to compare pre- and post-TME sexual dysfunction according to the approach of the inferior mesenteric vessels, directly on the IMA or from the inferior mesenteric vein (IMV) to the IMA.

Methods: Multicenter, prospective, controlled and randomized study of patients with rectal adenocarcinoma with neoadjuvant chemoradiotherapy, who will be randomized into two groups depending on the approach of the inferior mesenteric vessels. The main variable is pre and postoperative sexual dysfunction. The sample to be included will be 90 patients, 45 per group.

Detailed Description

Purpose: The "Total Mesorectal Excision" (TME) is the standard surgical technique for the treatment of rectal cancer. Up to 50% of sexual dysfunction is described after TME and up to 30% of urinary dysfunction. Although there are other factors, the main cause of postoperative genitourinary dysfunction is intraoperative injury of the autonomic pelvic nerves. One of the regions with more risk is the Inferior Mesenteric Artery (IMA). The main objective of the study is to compare pre- and post-TME sexual dysfunction according to the approach of the inferior mesenteric vessels, directly on the IMA or from the inferior mesenteric vein (IMV) to the IMA.

Methods: Multicenter, prospective, controlled and randomized study of patients with rectal adenocarcinoma with neoadjuvant chemoradiotherapy, who will be randomized into two groups depending on the approach of the inferior mesenteric vessels. The main variable is pre and postoperative sexual dysfunction. The secondary variables are visualization and preservation of the pelvic autonomic nerves, pre- and postoperative urinary dysfunction, pre and postoperative quality of life. The sample to be included will be 90 patients, 45 per group.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Outcomes Assessor)

Masking Description

The analysis of the results will be blind for the investigator

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age greater (or equal) to 18 years
  • Diagnosed of rectal adenocarcinoma at ≤ 15 cm from the anal margin (by rigid rectoscopy)
  • Candidate for neoadjuvant (chemoradiotherapy).
  • Scheduled laparoscopic radical TME surgery carried out by colorectal surgeons;
  • ASA I, II or III;
  • Informed consent present.

Exclusion Criteria

  • Under 18 years old;
  • Not Candidate for neoadjuvant (chemoradiotherapy);
  • Emergency surgery;
  • Recurrent neoplasms
  • Patient with a history of infra-abdominal, or pelvic surgery of the prostate, or radiotherapy prior to the current process;
  • Patients with severe sexual dysfunction and neurological alterations before surgery
  • Patients with neurogenic bladder before surgery.
  • Not to sign the informed consent

Outcomes

Primary Outcomes

Changes in sexual dysfunction pre- and post-Total Mesorectal Excision

Time Frame: 1 week before surgery and 12 months post-surgery

Sexual dysfunction pre- and post-Total Mesorectal Excision by sexual dysfunction scale IIEF-5

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Corporacion Parc Tauli
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Anna Pallisera-Lloveras

md, PhD

Corporacion Parc Tauli

Study Sites (1)

Loading locations...

Similar Trials